Dysbetalipoproteinemia

Dysbetalipoproteinemia, also known as familial dysbetalipoproteinemia, type III hyperlipoproteinemia, or broad-beta disease, is a disorder of lipoprotein metabolism characterized by the accumulation of intermediate-density lipoprotein (IDL) and chylomicron remnants in the blood. The condition is most commonly associated with homozygosity for the apolipoprotein E2 (APOE2) allele, though only a minority of APOE2 homozygotes develop clinical disease, as additional genetic or environmental factors (such as obesity, diabetes mellitus, hypothyroidism, or other metabolic conditions) are typically required to trigger overt hyperlipidemia. Rare dominant forms caused by specific heterozygous APOE mutations also exist. The disease primarily affects the cardiovascular system and the skin. Patients typically present in adulthood with elevated levels of both cholesterol and triglycerides, often in roughly equal proportions. Characteristic clinical features include xanthoma striata palmaris (yellowish lipid deposits in the creases of the palms), which are considered pathognomonic, as well as tuberous or tuberoeruptive xanthomas over the elbows and knees. Premature atherosclerosis is a major concern, with increased risk of coronary artery disease and peripheral vascular disease, particularly affecting the femoral and tibial arteries. Treatment involves addressing any underlying metabolic conditions that may be exacerbating the dyslipidemia, along with lifestyle modifications including dietary changes, weight management, and increased physical activity. Pharmacological therapy is often necessary and typically includes fibrates (such as gemfibrozil or fenofibrate) and/or statins, which are generally highly effective in normalizing lipid levels in these patients. With appropriate treatment, lipid levels can often be well controlled and cardiovascular risk substantially reduced. Regular monitoring of lipid profiles and cardiovascular health is recommended.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Dysbetalipoproteinemia